ATE292969T1 - Verwendung von nikotin oder derivaten und l-dopa zur behandlung von neurologischen krankheiten, insbesonder morbus parkinson - Google Patents
Verwendung von nikotin oder derivaten und l-dopa zur behandlung von neurologischen krankheiten, insbesonder morbus parkinsonInfo
- Publication number
- ATE292969T1 ATE292969T1 AT00960782T AT00960782T ATE292969T1 AT E292969 T1 ATE292969 T1 AT E292969T1 AT 00960782 T AT00960782 T AT 00960782T AT 00960782 T AT00960782 T AT 00960782T AT E292969 T1 ATE292969 T1 AT E292969T1
- Authority
- AT
- Austria
- Prior art keywords
- dopa
- nicotine
- disease
- derivatives
- treatment
- Prior art date
Links
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title abstract 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title abstract 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title abstract 2
- 229960002715 nicotine Drugs 0.000 title abstract 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title abstract 2
- 208000018737 Parkinson disease Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000000926 neurological effect Effects 0.000 title 1
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000037396 body weight Effects 0.000 abstract 1
- 230000000750 progressive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9911029A FR2798065B1 (fr) | 1999-09-02 | 1999-09-02 | Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson |
| PCT/FR2000/002428 WO2001015696A1 (fr) | 1999-09-02 | 2000-09-01 | Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE292969T1 true ATE292969T1 (de) | 2005-04-15 |
Family
ID=9549506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00960782T ATE292969T1 (de) | 1999-09-02 | 2000-09-01 | Verwendung von nikotin oder derivaten und l-dopa zur behandlung von neurologischen krankheiten, insbesonder morbus parkinson |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6911475B1 (de) |
| EP (1) | EP1212060B1 (de) |
| AT (1) | ATE292969T1 (de) |
| CA (1) | CA2383509C (de) |
| DE (1) | DE60019436T2 (de) |
| DK (1) | DK1212060T3 (de) |
| ES (1) | ES2241651T3 (de) |
| FR (1) | FR2798065B1 (de) |
| PT (1) | PT1212060E (de) |
| WO (1) | WO2001015696A1 (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69912808T2 (de) | 1999-12-08 | 2004-09-30 | Centre National De La Recherche Scientifique (C.N.R.S.) | Verwendung von Hymenialdisin und dessen Derivaten zur Herstellung therapeutischer Mittel |
| US20070225379A1 (en) * | 2001-08-03 | 2007-09-27 | Carrara Dario Norberto R | Transdermal delivery of systemically active central nervous system drugs |
| US8980290B2 (en) * | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
| WO2005039531A1 (en) * | 2003-10-10 | 2005-05-06 | Antares Pharma Ipl Ag | Transdermal pharmaceutical formulation for minimizing skin residues |
| US7198801B2 (en) * | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
| EP1307232B1 (de) * | 2000-08-03 | 2007-03-07 | Antares Pharma IPL AG | Neue zusammensetzung zur transdermalen und/oder transmukosalen wirkstoffanwendung mit geeignetem therapeutischen spiegel |
| US20040198706A1 (en) * | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
| KR100421585B1 (ko) | 2001-10-25 | 2004-03-09 | 한국전자통신연구원 | 시간분할 듀플렉스 시스템에서 이동국의 셀 탐색 시스템및 그 방법 |
| DE10338174A1 (de) | 2003-08-20 | 2005-03-24 | Lts Lohmann Therapie-Systeme Ag | Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit |
| US7387788B1 (en) | 2003-10-10 | 2008-06-17 | Antares Pharma Ipl Ag | Pharmaceutical compositions of nicotine and methods of use thereof |
| US7257577B2 (en) * | 2004-05-07 | 2007-08-14 | International Business Machines Corporation | System, method and service for ranking search results using a modular scoring system |
| US7780981B2 (en) | 2004-09-13 | 2010-08-24 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| WO2007124250A2 (en) | 2006-04-21 | 2007-11-01 | Antares Pharma Ipl Ag | Methods of treating hot flashes with formulations for transdermal or transmucosal application |
| US8067399B2 (en) | 2005-05-27 | 2011-11-29 | Antares Pharma Ipl Ag | Method and apparatus for transdermal or transmucosal application of testosterone |
| KR100699582B1 (ko) | 2005-07-11 | 2007-03-23 | 삼성전기주식회사 | 출력 버퍼회로 |
| WO2008067991A2 (en) * | 2006-12-08 | 2008-06-12 | Antares Pharma Ipl Ag | Skin-friendly drug complexes for transdermal administration |
| AU2011203482B2 (en) * | 2007-04-02 | 2014-09-04 | Parkinson's Institute | Methods and compositions for reduction of side effects of therapeutic treatments |
| ES2521494T3 (es) * | 2007-04-02 | 2014-11-12 | Parkinson's Institute | Métodos y composiciones para la reducción de los efectos secundarios de tratamientos terapéuticos |
| EP2729148A4 (de) * | 2011-07-06 | 2015-04-22 | Parkinson S Inst | Zusammensetzungen und verfahren zur behandlung von symptomen bei patienten mit morbus parkinson |
| WO2014172372A1 (en) | 2013-04-15 | 2014-10-23 | Northwestern University | Treatment for dopaminergic disorders |
| JP2018511355A (ja) | 2015-01-28 | 2018-04-26 | クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 薬剤送達方法及びシステム |
| US10679516B2 (en) | 2015-03-12 | 2020-06-09 | Morningside Venture Investments Limited | Craving input and support system |
| US10292977B2 (en) | 2016-04-11 | 2019-05-21 | Neurocea, LLC | Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases |
| US10143687B2 (en) | 2016-04-11 | 2018-12-04 | Neurocea, LLC | Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases |
| CA3049529A1 (en) | 2017-01-06 | 2018-07-12 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
| US11596779B2 (en) | 2018-05-29 | 2023-03-07 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| CA3119992A1 (en) | 2018-11-16 | 2020-05-22 | Morningside Venture Investments Limited | Thermally regulated transdermal drug delivery system |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5242935A (en) | 1992-03-06 | 1993-09-07 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
| US5232933A (en) * | 1992-05-21 | 1993-08-03 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
-
1999
- 1999-09-02 FR FR9911029A patent/FR2798065B1/fr not_active Expired - Fee Related
-
2000
- 2000-09-01 ES ES00960782T patent/ES2241651T3/es not_active Expired - Lifetime
- 2000-09-01 WO PCT/FR2000/002428 patent/WO2001015696A1/fr not_active Ceased
- 2000-09-01 US US09/653,717 patent/US6911475B1/en not_active Expired - Lifetime
- 2000-09-01 AT AT00960782T patent/ATE292969T1/de active
- 2000-09-01 PT PT00960782T patent/PT1212060E/pt unknown
- 2000-09-01 DE DE60019436T patent/DE60019436T2/de not_active Expired - Lifetime
- 2000-09-01 EP EP00960782A patent/EP1212060B1/de not_active Expired - Lifetime
- 2000-09-01 CA CA2383509A patent/CA2383509C/fr not_active Expired - Fee Related
- 2000-09-01 DK DK00960782T patent/DK1212060T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2383509C (fr) | 2012-08-14 |
| WO2001015696A1 (fr) | 2001-03-08 |
| PT1212060E (pt) | 2005-08-31 |
| DE60019436T2 (de) | 2006-02-02 |
| ES2241651T3 (es) | 2005-11-01 |
| DE60019436D1 (de) | 2005-05-19 |
| FR2798065B1 (fr) | 2003-09-05 |
| FR2798065A1 (fr) | 2001-03-09 |
| EP1212060B1 (de) | 2005-04-13 |
| EP1212060A1 (de) | 2002-06-12 |
| DK1212060T3 (da) | 2005-08-15 |
| US6911475B1 (en) | 2005-06-28 |
| CA2383509A1 (fr) | 2001-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE292969T1 (de) | Verwendung von nikotin oder derivaten und l-dopa zur behandlung von neurologischen krankheiten, insbesonder morbus parkinson | |
| Urban et al. | Long-term use of narcotic/antidepressant medication in the management of phantom limb pain | |
| NL970006I1 (nl) | Gebruik van indolon-derivaten voor het bereiden van geneesmiddelen ter behandeling van de ziekte vanParkinson. | |
| WO2001009118A3 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
| DE60022021D1 (de) | Zubereitungen enthaltend Apomorphin und Sildenafil und ihre Verwendung zur Behandlung von erektiler Dysfunktion | |
| TW200607511A (en) | Use of optically pure (S,S)-reboxetine in the manufacture of a medicament for the treatment or prevention of peripheral neuropathy | |
| MXPA05006940A (es) | Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide. | |
| DE236684T1 (de) | Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit. | |
| MXPA05012810A (es) | Formas de dosis oral de memantina. | |
| GB2285219B (en) | Use of norastemizole for the treatment of allergic disorders | |
| EP1201246A3 (de) | Verwendung von Thrombopoietin als Medikament zur Therapie und Vorbeugung der Thrombocytopenie | |
| IE61612B1 (en) | Antiparkinson ergoline derivatives | |
| IL194500A0 (en) | Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application | |
| ATE366581T1 (de) | Apoptotische körper zur verwendung in der behandlung von neurodegenerativen und sonstigen nervenerkrankungen | |
| RU2003127718A (ru) | Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости | |
| MY132437A (en) | New applications of lysozyme dimer | |
| BR0009380A (pt) | Tratamento de câncer melhorado comtemozolomida | |
| RU2006101061A (ru) | Азенапин для лечения шизофрении у пациентов с избыточной массой тела или предрасположенностью к избыточной массе тела | |
| KR900007434A (ko) | 시스타틴을 유효 성분으로하는 치료제 | |
| JPH10506097A (ja) | Ｊｅｔ ｌａｇを緩和するための方法と医薬 | |
| WO1996030016A3 (en) | Low dose ridogrel formulations and their use for the treatment of inflammatory bowel diseases | |
| RU2002129298A (ru) | Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера | |
| Myers et al. | Nocturnal cataclysms with myoclonus: a new side effect of clomipramine. | |
| LT2006024A (en) | Tetrapeptide regulating blood glucose level in diabetes mellitus | |
| KR20210097487A (ko) | 후코이단을 포함하는 수면장애 예방, 개선 또는 치료용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1212060 Country of ref document: EP |